Surgical Guidance of Head and Neck Squamous Cell Carcinoma enabled by a c-MET targeting fluorescent probe cMBP-ICG

Abstract

Surgical procedure guided by near infrared (NIR) fluorescence dye, that is administrated via intravenous injection, is appealing to researchers and doctors. Tumors such as head and neck squamous cell carcinoma (HNSCC), which is shallow, invasive, and heterogenous, hampered such effort due to poor delivery. Herein, we applied a peptide-based NIR fluorescence dye, cMBP-ICG, which can be administrated via topical application and specifically target tumor tissue via c-MET binding, in a clinical trial. Ten clinical cases, which were diagnoses (suspectable) HNSCC by attending physician with biopsy, were included. cMBP-ICG solutions were applied with gargle onto tissue surface in vivo preoperatively. One case with non-tumor lesion, one case with biopsy-negative carcinoma in situ, and one case with additional foci (excision area were extended according), were screened out. Intraoperative ex vivo fluorescence imaging, in which cMBP-ICG was coated onto mucosa surfaces and cross-sections of specimens, clearly outlined horizontal and vertical margins of the tumor. Its efficiency was not diminished by interference of previous chemo- and radio-therapy. Twenty lymph nodes were also imaged upon cMBP-ICG coating, in which two out of two tumor-positive nodes were screened out with an accuracy of 100%. Fluorescence intensity from cMBP-ICG was found positively corelated to differentiation degree of HNSCC. In summary, topical application of cMBP-ICG was capable of differentiating preoperative tumor, revealing concealed foci, outlining margin of tumor intraoperatively, and detecting metastasized lymph nodes.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

ChiCTR2200058058

Funding Statement

This work was funded by the National Scientific Foundation of China (91859202 and 82172049).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Institutional review board of Chinese Clinical Trial Registry (ChiCTR2200058058 ) and medical ethics committee of the Shanghai Ninth People's Hospital Affiliatedaffiliated to the Shanghai Jiaotong University, schoolSchool of medicineMedicine (SH9H-2020-T147-2)gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

留言 (0)

沒有登入
gif